Patents by Inventor John Knopf

John Knopf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lefty polypeptides and derivatives thereof
    Patent number: 7612040
    Abstract: The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, Lefty polypeptides are useful in the treatment of a variety of disorders, including, for example, neuronal diseases, muscle and bone conditions, and metabolic disorders.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: November 3, 2009
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth
    Patent number: 7612041
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: November 3, 2009
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Cerberus/coco derivatives and uses thereof
    Publication number: 20090192080
    Abstract: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.
    Type: Application
    Filed: August 20, 2007
    Publication date: July 30, 2009
    Inventors: John Knopf, Jasbir Seehra
  • BMP10 propeptides and related methods
    Publication number: 20090149372
    Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.
    Type: Application
    Filed: December 9, 2008
    Publication date: June 11, 2009
    Applicant: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, John Knopf
  • Activin-actriia antagonists and uses for promoting bone growth in cancer patients
    Publication number: 20090142333
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
    Type: Application
    Filed: February 1, 2008
    Publication date: June 4, 2009
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Activin-actriia antagonists and uses for decreasing or inhibiting FSH secretion
    Publication number: 20090118188
    Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
    Type: Application
    Filed: September 17, 2008
    Publication date: May 7, 2009
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman
  • Activin-ActRIIa antagonists and uses for promoting bone growth
    Publication number: 20090099086
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: September 24, 2008
    Publication date: April 16, 2009
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ALK7 and myostatin inhibitors and uses thereof
    Publication number: 20090098114
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Application
    Filed: October 17, 2008
    Publication date: April 16, 2009
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Activin-ActRIIa antagonists and uses for promoting bone growth
    Publication number: 20090098113
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: September 24, 2008
    Publication date: April 16, 2009
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Uses of cerberus, Coco and derivatives thereof
    Publication number: 20090082270
    Abstract: The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.
    Type: Application
    Filed: December 10, 2007
    Publication date: March 26, 2009
    Applicant: Acceleron Pharma Inc.
    Inventors: Asya Grinberg, John Knopf, Ravindra Kumar, Jasbir Seehra
  • Activin-actriia antagonists and uses for treating or preventing breast cancer
    Publication number: 20090074768
    Abstract: In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans.
    Type: Application
    Filed: February 1, 2008
    Publication date: March 19, 2009
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • IL-13 binding agents
    Patent number: 7501121
    Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: March 10, 2009
    Assignee: Wyeth
    Inventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
  • Modified TGF-Beta Superfamily Polypeptides and Related Methods
    Publication number: 20090042780
    Abstract: The disclosure relates to modified TGF-beta polypeptides. Certain modified polypeptides disclosed herein are chimeric, containing a conserved framework portion from one protein of this family (e.g., Nodal) and variable loops that mediate receptor interaction derived from a second protein of this family (e.g., BMP-2). The chimeras will generally be designed so as to mimic a biological effect of the family member from which the variable loops are derived. Other modified TGF-polypeptides disclosed herein have one or more post-translational modifications that may be situated in one or more core domains.
    Type: Application
    Filed: May 20, 2005
    Publication date: February 12, 2009
    Applicant: ACCELERON PHARMA INC
    Inventors: John Knopf, Jasbir Seehra
  • Variants derived from ACTRIIB and uses therefor
    Publication number: 20090005308
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
    Type: Application
    Filed: February 4, 2008
    Publication date: January 1, 2009
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • GDF3 propeptides and related methods
    Patent number: 7465706
    Abstract: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: December 16, 2008
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ALK7 and myostatin inhibitors and uses thereof
    Patent number: 7456149
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: November 25, 2008
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra
  • BMP-3 antibodies and related methods
    Publication number: 20080241164
    Abstract: The present invention provides compositions and methods for promoting bone growth. The present invention also provides methods of screening compounds that modulate BMP-3A or BMP-3B activity. The compositions and methods provided herein are useful in modulating bone growth.
    Type: Application
    Filed: November 19, 2007
    Publication date: October 2, 2008
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ALK1 receptor and ligand antagonist and uses thereof
    Publication number: 20080175844
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: November 2, 2007
    Publication date: July 24, 2008
    Applicant: Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Robert Scott Pearsall, Ravindra Kumar, Jasbir Seehra
  • Tgf Derepressors and Uses Related Thereto
    Publication number: 20080119396
    Abstract: The application is directed to TGF analogs/derepressors that bind to and neutralize cystine knot-containing BMP antagonists—such as the CAN subfamily of Cystine-knot proteins including sclerostin. The subject TGF derepressors can be prepared as substantially pyrogen-free pharmaceutical compositions for administration to mammals, in treating diseases such as bone diseases including osteoporosis, and any conditions with lesser-than-desired amount of BMP activity.
    Type: Application
    Filed: May 27, 2005
    Publication date: May 22, 2008
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Cerberus/Coco derivatives and uses thereof
    Patent number: 7316998
    Abstract: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: January 8, 2008
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra